Loading stock data…
VYGR
$3.46+0.09 (+2.52%)
Market OpenUpdated 3:57 PM EDT
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Voyager Therapeutics, Inc. in the Healthcare sector is trading at $3.46 with a market capitalization of $218M. Wall Street consensus targets $14.89 (9 analysts), implying a +330.9% move over the next 12 months. The stock is currently 38% below its 52-week high of $5.55, remaining 15.5% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +330.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$3.46
Potential Downside
0%
Whystock Fair Value$3.46
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$217.52M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.26
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-67.16%
Volume
Today's trading volume
402,482
Recent News
Here's Why We're A Bit Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
What Voyager Therapeutics Inc (VYGR) Has Gained on Its Therapy Programs
Voyager Therapeutics Inc (NASDAQ:VYGR) is one of the best gene therapy stocks to buy in 2026. While the stock has risen only a modest 30% over the past year, analysts believe it can explode more than 250% over the next 12 months as the company advances its drug programs. On May 13, Voyager Therapeutics announced […]
Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates
Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of +12.96% and -74.02%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics Conference: CEO Calls 2026 “Year of Tau,” Eyes BBB Capsid Clinic Debut
Voyager Therapeutics (NASDAQ:VYGR) CEO Al Sandrock outlined several 2026 priorities in a discussion focused on the company’s tau-directed pipeline and its newer blood-brain barrier (BBB)-penetrant capsid platform. Sandrock described 2026 as “the year of tau,” while also pointing to upcoming clinical
Does Voyager Therapeutics’ (VYGR) Widening Annual Loss Redefine the Risk-Reward in Its Neurology Pipeline?
Voyager Therapeutics, Inc. reported fourth-quarter 2025 results showing a net loss of US$27.43 million versus US$34.49 million a year earlier, while its full-year 2025 net loss widened to US$119.72 million from US$65.00 million. Although the quarterly loss per share from continuing operations narrowed to US$0.47 basic (US$0.46 diluted), the full-year loss per share increased to US$2.04 basic and diluted, underscoring the cost of advancing its neurology-focused pipeline. We’ll now examine how...